Skip to main content
OpenTrials

Clinical trial condition

Purpura, Thrombotic Thrombocytopenic

Explore clinical trials studying Purpura, Thrombotic Thrombocytopenic. Study availability and eligibility vary by location and protocol.

39 public trials 12 recruiting studies
Refine in advanced search Browse all conditions

Purpura, Thrombotic Thrombocytopenic trial results

Completed

Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

NCT05468320

Conditions
Blood Coagulation Disorders, Blood Platelet Disorders, Cytopenia, +14 more
Locations
  • University of Alabama- Site Number : 8400011 Birmingham, Alabama, United States
  • Johns Hopkins University- Site Number : 8400007 Baltimore, Maryland, United States
  • Duke University Medical Center Site Number : 8400022 Durham, North Carolina, United States
  • The Ohio State University Comprehensive Cancer Center - Site Number : 8400001 Columbus, Ohio, United States
View all 27 locations
View Trial Details
Completed

A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

NCT04074187

Conditions
Blood Coagulation Disorders, Blood Platelet Disorders, Cytopenia, +14 more
Locations
  • Investigational Site Number 3920009 Iruma-Gun, Japan
  • Investigational Site Number 3920014 Kanazawa, Japan
  • Investigational Site Number 3920007 Kashihara-shi, Japan
  • Investigational Site Number 3920013 Kawasaki-Shi, Japan
View Trial Details
Completed

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

NCT02553317

Conditions
Acquired Thrombotic Thrombocytopenic Purpura, Blood Coagulation Disorders, Blood Platelet Disorders, +14 more
Locations
  • Investigator Site Birmingham, Alabama, United States
  • Investigator Site Los Angeles, California, United States
  • Investigator Site Atlanta, Georgia, United States
  • Investigator Site Boston, Massachusetts, United States
View all 101 locations
View Trial Details
Completed

Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

NCT01151423

Conditions
Acquired Thrombotic Thrombocytopenic Purpura, Blood Coagulation Disorders, Blood Platelet Disorders, +14 more
Locations
  • Investigator Site Los Angeles, California, United States
  • Investigator Site Washington D.C., District of Columbia, United States
  • Investigator Site Atlanta, Georgia, United States
  • Investigator Site St Louis, Missouri, United States
View all 51 locations
View Trial Details
Completed

Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

NCT03922308

Conditions
Acquired Thrombotic Thrombocytopenic Purpura (aTTP), Blood Coagulation Disorders, Blood Platelet Disorders, +14 more
Locations
  • The University of Alabama at Birmingham Birmingham, Alabama, United States
  • Brigham and Women's Hospital Boston, Massachusetts, United States
  • University of Minnesota Minneapolis, Minnesota, United States
  • University Hospitals Cleveland Medical Center Cleveland, Ohio, United States
View all 24 locations
View Trial Details
Completed

Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

NCT02878603

Conditions
Acquired Thrombotic Thrombocytopenic Purpura, Blood Coagulation Disorders, Blood Platelet Disorders, +14 more
Locations
  • Investigator site St Louis, Missouri, United States
  • Investigator site Valhalla, New York, United States
  • Investigator Site Durham, North Carolina, United States
  • Investigator Site Columbus, Ohio, United States
View all 45 locations
View Trial Details

Related conditions